share_log

Arcutis Biotherapeutics | 10-Q/A: Quarterly report (Amendment)

Arcutis Biotherapeutics | 10-Q/A: Quarterly report (Amendment)

Arcutis Biotherapeutics | 10-Q/A：季度报表(修正版)
美股SEC公告 ·  2024/07/25 04:15

Moomoo AI 已提取核心信息

Arcutis Biotherapeutics has filed Amendment No. 1 to its Q1 2024 Quarterly Report on Form 10-Q to include previously omitted information about a Rule 10b5-1 trading arrangement. The amendment specifically addresses the Original Filing dated May 14, 2024, focusing on revising Part II Item 5 "Other Information" section.The key addition to the filing reveals that Howard G. Welgus, M.D., a Board member, established a Rule 10b5-1 trading plan on March 5, 2024. The plan allows for the potential sale of up to 93,386 shares of common stock and the exercise and sale of up to 26,614 options between June 4, 2024, and May 30, 2025.The amendment maintains all other aspects of the Original Filing unchanged, with no modifications to financial statements or other disclosures. New certifications from the company's principal executive officer and principal financial officer have been included as required by Rule 12b-15 of the Securities Exchange Act of 1934, though certain certification paragraphs were omitted as no financial statements were included in this amendment.
Arcutis Biotherapeutics has filed Amendment No. 1 to its Q1 2024 Quarterly Report on Form 10-Q to include previously omitted information about a Rule 10b5-1 trading arrangement. The amendment specifically addresses the Original Filing dated May 14, 2024, focusing on revising Part II Item 5 "Other Information" section.The key addition to the filing reveals that Howard G. Welgus, M.D., a Board member, established a Rule 10b5-1 trading plan on March 5, 2024. The plan allows for the potential sale of up to 93,386 shares of common stock and the exercise and sale of up to 26,614 options between June 4, 2024, and May 30, 2025.The amendment maintains all other aspects of the Original Filing unchanged, with no modifications to financial statements or other disclosures. New certifications from the company's principal executive officer and principal financial officer have been included as required by Rule 12b-15 of the Securities Exchange Act of 1934, though certain certification paragraphs were omitted as no financial statements were included in this amendment.
Arcutis Biotherapeutics已提交2024年第一季度10-Q表格的第1号修正案，以包含之前遗漏的有关规则10b5-1交易安排的信息。该修正案特别针对2024年5月14日的原始提交，重点修订第二部分第5项“其他信息”部分。文件的关键补充披露了董事会成员Howard G. Welgus万.D.于2024年3月5日建立了一个规则10b5-1交易计划。该计划允许在2024年6月4日至2025年5月30日之间，最多出售93,386股普通股及行使和出售最多26,614个期权。修正案保持原始提交的所有其他方面不变，没有对基本报表或其他披露进行修改。根据1934年证券交易法第120亿.15条的要求，已包含来自公司首席执行官和信安金融首席财务官的新认证，尽管由于该修正案中未包含财务报表，某些认证段落被省略。
Arcutis Biotherapeutics已提交2024年第一季度10-Q表格的第1号修正案，以包含之前遗漏的有关规则10b5-1交易安排的信息。该修正案特别针对2024年5月14日的原始提交，重点修订第二部分第5项“其他信息”部分。文件的关键补充披露了董事会成员Howard G. Welgus万.D.于2024年3月5日建立了一个规则10b5-1交易计划。该计划允许在2024年6月4日至2025年5月30日之间，最多出售93,386股普通股及行使和出售最多26,614个期权。修正案保持原始提交的所有其他方面不变，没有对基本报表或其他披露进行修改。根据1934年证券交易法第120亿.15条的要求，已包含来自公司首席执行官和信安金融首席财务官的新认证，尽管由于该修正案中未包含财务报表，某些认证段落被省略。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    重磅财报来袭！2025年中国资产前景如何？
    近期，Goldman Sachs、Morgan Stanley、Appaloosa LP等多家机构唱好中国资产。 🎙️讨论： 1. Deepseek引发了中国资产的一轮上涨。你对未来市场的看法如何？ 2. 包括 $阿里巴巴 (BABA.US)$ 和 展开
    阿里巴巴(临时代码)2024财年第四季度业绩电话会